Session Details

Workshop 1 - NAVRMA Joint Session Veterinary medicine in developing cell-based therapies and bioengineering approach for human clinical use
Friday, September 13, 2019 10:45 AM - 12:15 PM
Plenary Hall
Daniel Weiss, MD, PhD, University of Vermont, USA
Tracy Webb, DVM, PhD, Colorado State University, USA

Companion animal models scaffold to regenerative medicine therapeutics in humans
Andrew Hoffman, DVM, DVSc, School of Veterinary Medicine, University of Pennsylvania, USA
Learning objectives:
•      Review of Companion Animal Models
•      Review of Process of Enrolling Companion Animals
•      Review of Clinical Trials of Stem Cells in Companion Animals

Cell & Gene Therapies for Joint Disease and Cartilage Repair Using the Horse as a Model for Human Disease
Kyla Ortved, DVM, PhD, University of Pennsylvania School of Veterinary Medicine, USA
Learning Objectives:
•      Evaluate current MSC-based therapies for resurfacing cartilage and treating osteoarthritis.
•      Discuss different gene therapy options for joint disease.
•      Summarize the clinical use of gene and cell therapies for joint disease in the horse.

Equine models of joint disease for the investigation of cell-based therapies
Aimee Colbath, VMD, PhD, DACVS-LA, Michigan State University College of Veterinary Medicine, USA
Learning objectives:
•      Describe why the horse is an ideal model for testing cell-based therapies for joint disease
•      Describe equine surgical, experimental models of osteoarthritis appropriate for testing cell-based therapies
•      Describe non-surgical, experimental models of joint inflammation appropriate for testing of cell-based therapies

How naturally occurring disease models in dogs and cats inform human clinical trials
Dori Borjesson, BA, DVM, MPVM, PhD, UC Davis School of Veterinary Medicine, USA
Learning objectives:
•      Understand the role of naturally occurring models of dog and cat disease to inform human cell therapy clinical trials
•      Define some best practices for working with veterinarians and clinical trials in cell therapy arena
•      Understand how data including safety, efficacy, biomarker discovery and even mechanism of action studies performed in dogs and cats can be leveraged at the FDA